SCHEMBL1637175

SCHEMBL1637175

CC(=O)Nc1ccc([N+](=O)[O-])c(F)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
NPSR1 Q6W5P4 3/20 0.52
KMT2A Q03164 4/20 0.50
HTT P42858 2/20 0.50
POLB P06746 4/20 0.47
PKM P14618 2/20 0.47
ALDH3A1 P30838 1/20 0.46
ALDH1A1 P00352 5/20 0.46
LMNA P02545 3/20 0.46
GALR2 O43603 1/20 0.46
MITF O75030 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HPGD P15428 1/20 0.46
XBP1 P17861 1/20 0.46
CCR6 P51684 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
PDE7A Q13946 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123707 0.87 NPSR1 (0.55) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL30539486 0.87 NPSR1 (0.55) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL5647147 0.81 PKM (0.55) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL3615057 0.79 ALDH1A1 (0.47) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL12144665 0.79 AR (0.55) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL6789579 0.79 POLB (0.68) MAPTNPSR1KMT2APOLBPKM
SCHEMBL7432485 0.78 NPSR1 (0.50) MAPTNPSR1KMT2AHTTPOLB
SCHEMBL10472153 0.78 HDAC1 (0.47) MAPTHTTPOLBPKMALDH1A1
SCHEMBL15594102 0.78 ALDH1A1 (0.50) MAPTKMT2AHTTPOLBALDH1A1
SCHEMBL571816 0.77 MAPT (0.64) MAPTNPSR1KMT2AHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786828-B1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2012-01-11 EP disclosed
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed
EP-1786828-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX (FR) 2007-05-23 EP disclosed
WO-2006030119-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY bioMérieux (FR) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP MAPT 3751/4885NPSR1 342/4885KMT2A 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.